Relationship between prostate-specific antigen bounce body fat distribution and body mass index in permanent seed brachytherapy for prostate cancer

Brachytherapy. 2012 May-Jun;11(3):214-8. doi: 10.1016/j.brachy.2011.05.009. Epub 2011 Jun 22.

Abstract

Purpose: To analyze the influence of body mass index (BMI) and adipose tissue distribution on prostate-specific antigen (PSA) bounce after iodine-125 prostate brachytherapy.

Methods and materials: We studied 20 patients who had PSA bounce (≥0.50ng/mL) after exclusive prostate brachytherapy. These patients were compared with 48 patients without a bounce (<0.50ng/mL). All patients in the comparison group had a followup of ≥24 months and a last PSA ≤0.5ng/mL. Within these 48 patients, there was a group matched for age (n=20). Univariate and multivariate logistic models were estimated to assess the association between age, baseline PSA, prostate volume, D(90), visceral fat (VF) volume, and BMI on PSA-bouncing status.

Results: When comparing the patients with a bounce to those without, only BMI showed a significantly different distribution (mean, 25.18 vs. 27.47kg/m(2); p=0.0342). On a multivariate analysis, BMI had an odds ratio of 0.85 (95% confidence interval, 0.71-0.99, p=0.049), indicating that an increase of 1kg/m(2) in BMI is associated with a 15% reduction in the odds of having a bounce. In the univariate analysis with the matching patients, BMI was a significant predictor of a bounce (p=0.0147). In the multivariate conditional logistic model, BMI showed a trend toward an influence on a bounce (p=0.0615). All other factors, including VF, did not have any influence on a PSA bounce.

Conclusions: Patients with a lower BMI are more likely to experience a PSA bounce ≥0.50ng/mL. VF did not have an influence on a PSA bounce.

Publication types

  • Clinical Trial

MeSH terms

  • Age Factors
  • Aged
  • Body Fat Distribution*
  • Body Mass Index*
  • Brachytherapy / methods*
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Grading
  • Organ Size / radiation effects
  • Prostate / pathology
  • Prostate-Specific Antigen / blood*
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / radiotherapy*

Substances

  • Prostate-Specific Antigen